In addition, the FDA authorized dostarlimab (JEMPERLI®), the fourth anti-PD-1 antibody, for the treatment of mismatch repair-deficient (dMMR) endometrial cancer and dMMR solid tumors in 2021 [16,17]. The gene discussed is PDCD1; the disease is endometrial cancer.